Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial
Background Oncolytic viruses (OVs) are promising immunotherapeutics to treat immunologically cold tumors. However, research on the mechanism of action of OVs in humans and clinically relevant biomarkers is still sparse. To induce strong T-cell responses against solid tumors, TILT-123 (Ad5/3-E2F-d24-...
Saved in:
Main Authors: | Tuomo Alanko, Akseli Hemminki, Víctor Cervera-Carrascón, Riikka Havunen, Kristian Taipale, Dafne C A Quixabeira, Jorma Sormunen, Katriina Peltola, Suvi Sorsa, Santeri A Pakola, Elise Jirovec, Lyna Haybout, Claudia Kistler, Tatiana V Kudling, Victor Arias, James H A Clubb, Mirte van der Heijden, Teijo Pellinen, Joao M Santos |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-01-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/13/1/e010493.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial
by: Matthew Stephen Block, et al.
Published: (2025-02-01) -
Oncolytic Immunotherapy: Where Are We Clinically?
by: Akseli Hemminki
Published: (2014-01-01) -
Survival, Incidence, and Mortality Trends in Female Cancers in the Nordic Countries
by: Filip Tichanek, et al.
Published: (2023-01-01) -
The challenge of automated tutoring in Web-based learning environments for information retrieval instruction
by: Sormunen Eero; Pennanen, et al.
Published: (2004-01-01) -
Stinging Nettle (<i>Urtica dioica</i>) Roots: The Power Underground—A Review
by: Françoise Martz, et al.
Published: (2025-01-01)